Literature DB >> 16393287

Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection.

A de Gottardi1, V Pazienza, P Pugnale, F Bruttin, L Rubbia-Brandt, C E Juge-Aubry, C A Meier, A Hadengue, F Negro.   

Abstract

BACKGROUND: Steatosis in chronic hepatitis C is associated with inflammation and accelerated fibrogenesis. AIM: To assess the contribution of peroxisome proliferator-activated receptor-alpha and -gamma to the pathogenesis of hepatitis C virus associated steatosis is unknown.
METHODS: We measured peroxisome proliferator-activated receptor (PPAR)-alpha and -gamma mRNA by quantitative polymerase chain reaction in liver biopsies of 35 genotype 1 and 22 genotype 3 infected patients and in Huh7 cells expressing hepatitis C virus 1b or 3a core protein.
RESULTS: PPAR-alpha mRNA was significantly reduced in livers of patients with genotype 3 compared with genotype 1. Steatosis was associated to a decreased expression of PPAR-alpha in genotype 1, but not in genotype 3. PPAR-gamma expression was significantly lower in genotype 3 compared with genotype 1 and steatosis was associated to decreased levels of PPAR-gamma, but only in genotype 1. There was no significant relationship between PPARs mRNA levels and liver activity or fibrosis. Expression of the hepatitis C virus 3a core protein was associated with an increase in triglyceride accumulation and with a significant reduction of PPAR-gamma mRNA compared with hepatitis C virus 1b.
CONCLUSIONS: The presence of steatosis and hepatitis C virus genotype 3 are both associated with a significant down-regulation of PPARs. These receptors, and also additional factors, seem to play a role in the pathogenesis of hepatitis C virus-associated steatosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393287     DOI: 10.1111/j.1365-2036.2006.02729.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  49 in total

Review 1.  Interaction between hepatitis C virus and metabolic factors.

Authors:  Yasunori Kawaguchi; Toshihiko Mizuta
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 2.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  Current and novel therapies for the treatment of nonalcoholic steatohepatitis.

Authors:  David van der Poorten; Jacob George
Journal:  Hepatol Int       Date:  2007-07-26       Impact factor: 6.047

4.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

5.  MicroRNA-185-5p mediates regulation of SREBP2 expression by hepatitis C virus core protein.

Authors:  Min Li; Qi Wang; Shun-Ai Liu; Jin-Qian Zhang; Wei Ju; Min Quan; Sheng-Hu Feng; Jin-Ling Dong; Ping Gao; Jun Cheng
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

6.  Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus.

Authors:  Kohichiroh Yasui; Yuichi Harano; Hironori Mitsuyoshi; Kazuhiro Tsuji; Mio Endo; Tomoaki Nakajima; Masahito Minami; Yoshito Itoh; Yoh Zen; Yasuni Nakanuma; Toshikazu Yoshikawa; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

Review 7.  Hepatitis C virus infection: Are there still specific problems with genotype 3?

Authors:  Claire Gondeau; Georges Philippe Pageaux; Dominique Larrey
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 8.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 9.  Production and pathogenicity of hepatitis C virus core gene products.

Authors:  Hui-Chun Li; Hsin-Chieh Ma; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance.

Authors:  Francesco Negro
Journal:  PPAR Res       Date:  2009-01-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.